NYSE:ANRO Alto Neuroscience Q1 2025 Earnings Report $26.99 -0.19 (-0.69%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alto Neuroscience EPS ResultsActual EPS-$0.53Consensus EPS -$0.59Beat/MissBeat by +$0.06One Year Ago EPSN/AAlto Neuroscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlto Neuroscience Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time4:00PM ETUpcoming EarningsAlto Neuroscience's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alto Neuroscience Earnings HeadlinesAlto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 22 at 4:15 AM | americanbankingnews.comAlto Neuroscience Announces Participation in Upcoming Investor ConferencesSeptember 9, 2026 | businesswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 25 at 1:00 AM | Base Camp Trading (Ad)Alto Neuroscience Promotes Smith to President, CFOAugust 27, 2026 | tipranks.comAlto Neuroscience Promotes Nick Smith to President and Chief Financial OfficerAugust 27, 2026 | businesswire.comAlto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?August 17, 2026 | uk.finance.yahoo.comSee More Alto Neuroscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email. Email Address About Alto NeuroscienceAlto Neuroscience (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies. Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia. Its programs have included ALTO-100, an oral therapy being studied in depression, and ALTO-300, an investigational therapy evaluated as an adjunctive treatment for major depressive disorder. The company has also pursued additional neuroscience programs intended to address cognitive and other symptoms associated with psychiatric disease. Founded in 2019, Alto Neuroscience is headquartered in Redwood City, California, and conducts its clinical development activities primarily through research and clinical-trial networks. The company became publicly traded on the New York Stock Exchange in 2024. Its business remains focused on advancing biomarker-informed treatments through clinical development rather than commercializing an established portfolio of marketed products.View Alto Neuroscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just Strengthened Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
